Drug profile · INN
rifampicin
RIMYCIN 300
rifampicin (RIMYCIN 300) is a bacterial dna-directed rna polymerase inhibitor. Associated with Alphapharm Pty Ltd.
TGA: approved
Patents linked 0
Pipeline programs 10
News articles 0
Drug details — rifampicin
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 10
- Data quality
- 0.81
Quick answer
rifampicin (RIMYCIN 300) is a bacterial dna-directed rna polymerase inhibitor. Associated with Alphapharm Pty Ltd.
Key facts
INN rifampicin
Brand RIMYCIN 300
Mechanism Bacterial DNA-directed RNA polymerase inhibitor
Target Bacterial DNA-directed RNA polymerase
Originator Alphapharm Pty Ltd
Mechanism of action
Bacterial DNA-directed RNA polymerase inhibitor
Primary target: Bacterial DNA-directed RNA polymerase
Approval history
| Authority | Status | Date |
|---|---|---|
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is rifampicin?
rifampicin (RIMYCIN 300) is a bacterial dna-directed rna polymerase inhibitor. Associated with Alphapharm Pty Ltd.
What is the brand name for rifampicin?
RIMYCIN 300 is a marketed brand name for rifampicin. Check FDA Drugs@FDA for the current US label holder and prescribing information.